Bio Screening Industry News

The biotechnology company continues its strong growth (+50% tendency) and
reinforces its international leadership in the development and supply of genetically
modified animal models. The products henceforth available from the catalogue
have already attracted Pfizer, GSK, BMS and Servier.
Lyon (France), 19 November 2007 - genOway, a biotechnology company specialized in
the development of genetically modified research models for the biopharmaceutical industry
today announces today the launching of its catalogue activity, based on the development
and supply of standardized tools.
This offer of animal models developed by genOway’s R&D teams or via the acquisition of
exclusive and non-exclusive licenses from prestigious academic laboratories such as Yale
University (Connecticut), the Hubrecht Institute (Netherlands), and the University of
Michigan is based on the supply of ready-for-use tools selectable from the catalogue.
The biological profile of these new animal models offers numerous advantages for biomedical
researchers: rapid availability, acquisition of biological predictability of the effects on the
human organism and a shortening the development cycle of the therapeutic solutions.
To date, genOway has elaborated a catalogue of standardized products - of which the
company retains the entire of intellectual property - spanning four major therapeutic axes:
- Inflammatory and metabolic pathologies (diabetes, obesity)
- Diseases of the central nervous system (depression, anxiety)
- Infectious diseases and allergy
- Gastroenterology.
In the area of metabolic illnesses, this offer has already attracted many major players in the
biopharmaceutical industry, such as Pfizer, GlaxoSmithKline, Bristol-Myers Squib and
Servier. genOway registed in mid-November 2007 an order sheet of over 0.8 million euros in
this domain.
Alexandre Fraichard, CEO of genOway, stated : “We are delighted to observe the success
achieved by our catalogue models. Recognition by many major pharmaceutical companies
validates our choices and our technical platform. Moreover, genOway benefits from
privileged links with the most cutting edge academic teams at international level, which
grant us exclusive and non-exclusive licenses on the animal models which we judge
pertinent. Thus our catalogue of standardized products will become richer in the coming
months with new proprietary models. We intend to continue our proactive license
acquisition policy, and have other licenses currently in negotiation”.
Kader Thiam, VP Transgenic Technologies at genOway added: “Through this new commercial
offer, genOway can now offer two distinct responses to the same demand from industrial
clients. The latter can now choose between customized development of genetically modified
animal models and the acquisition of standardized and more rapidly available animal models.
This approach reinforces our image as the reference point supplier for the entirety of
biomedical research”.
To date, genOway makes its expertise available to over 40 major biopharmaceutical groups
and 160 academic institutions, either through customized development of genetically
modified research animal models or through its emerging activity of sale of proprietary
models.
About genOway:
genOway(ALTERNEXT-NYSE:ALGEN)is a biotechnology company dedicated to the
development of geneticallymodified animal models aimed at enhancing thesecurity and
relevancy ofin vivo research projects. Focusing its efforton the mouse and rat,genOway’s
expertise combined transgenesictechnologies such aspronuclear microinjection, Knockout,
Knock-in,Knock- down, pointmutation, humanization combined with innovative patented
technologiesadapted to target validation, in vivo drugscreening, drug efficacy andsafety
testing program. Collaborations withworldwide leaders (CharlesRiver Laboratories,
Invitrogen, Tet systems,etc..) enable genOway toprovide its customer with a complete
portfolioof products and servicesfor all aspects of model generation and characterization.
Operating in22 countries in Europe, North America and Asia, genOway has developed more
than 450 rat and mouse lines for 40 companies and 160 research institutions. Thanks to its
industrializedproduction facilities,genOway is involved in large-scale projects with several
academic centers (German National Genome Research Network, University College London,
King’s College London, Max Planck Institute) and with pharmaceutical companies
(BayerCorp, Boehringer Ingelheim,Johnson& Johnson).
For more information consult:www.genoway.com
Contacts:
Marie Norbert - genOway - norbert@genoway.com
Contact for investors:
Gilles de Poncins , CFO - genOway - finances@genoway.com
Milestones - Press & Investors Relation
Bruno Arabian
Tel. : +33 170 08 04 13
E-mail : milestones@milestones-fr.com
Warning: This press release expressly contains, in an implicit manner,certain prospective
statements concerning genOway and its activity.These statements rely on certain risks, known
or unknown, uncertainty or onother factors that may lead to actual results, financial
conditions,performance or achievements on the part of genOway that may differ significantly
from the results, financial conditions, performance or achievements expressed or implied in
these prospective statements.genOway is issuing this press release on the present date and is
not committed to update the prospective statements contained therein, either as a result of new
information, future events or other. For a description of the risks or uncertainty of
a nature to cause a difference between genOway’s actual results, financial conditions,
performance or achievements and those contained in the prospective statements, please refer to
the section on “Risk Factors'’on the Prospectus available on the genOway website:
http://www.genoway.com